Value through Innovation11 February 2016

Boehringer Ingelheim Group of companies

 

    Financial Highlights

    Boehringer Ingelheim group of companies
     
    2014 2013 Change
    Net sales
    13,317 14,065 - 5 %
    Net sales by region
       
    Europe
    31% 30 %
    Americas
    44% 46 %  
    Asia, Australasia, Africa
    25% 24 %  
    by business
         
    Prescription Medicines 76% 77 %  
    Consumer Health Care 11% 11 %  
    Animal Health 8% 8 %  
    Biopharmaceuticals 4% 3 %  
    Industrial Customers and other sales 1% 1 %  
           
    Research and Development
    2,654 2,743  - 3 %
    Personnel costs
    4,116 4,071 + 1 %
    Average number of employees
    47,743 47,492 + 1 %
    Operating income
    2,140 2,114 + 1 %
    Operating income as % of net sales
    16.1% 15.0 %  
    Income after taxes
    1,047 1,324 - 21 %
    Income after taxes as % of net sales
    7.9% 9.4 %  
    Shareholders' equity
    8,111 7,122 + 14 %
    Return on shareholders' equity
    14.7% 21.4 %  
    Cash Flow
    1,850 2,129 - 13 %
    Investments in tangible assets
    548 558 - 2 %
    Depreciation of tangible assets
    449 640 - 30 %


    Amounts in millions of EUR, unless otherwise indicated